


This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently amended) A method of providing cardioprotection, or protecting against reperfusion injury, or protecting against ischemic injury, in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, beginning at a time less than ten minutes after the onset of reperfusion, and continuing for a period of more than 30 minutes following the onset of reperfusion.
2. (Previously presented) A method according to claim 1, wherein the cardioprotection is provided prior to, during, or following cardiac surgery.
3. (Previously presented) A method according to claim 1, wherein the cardioprotection is provided prior to, during, or following ischemic attack.
4. (Currently amended) A method according to claim 1, wherein the administering of the compound begins at the onset of reperfusion, and continues for a period of more than 30 minutes following the onset of reperfusion.
5. (Previously presented) A method according to claim 1, wherein the administering of the compound is continued for a period of more than 70 minutes after the onset of reperfusion.
6. (Previously presented) A method according to claim 1, wherein the compound is of the formula



or a pharmaceutically acceptable salt thereof.


7. (Previously presented) A method according to claim 1, wherein the compound is administered as a pharmaceutically acceptable salt thereof.

8. (Previously presented) A method according to claim 1, wherein the compound administered is contained in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of the compound.

9. (Currently amended) A method of providing cardioprotection, or protecting against reperfusion injury, or protecting against ischemic injury, in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, beginning at a time 10 minutes ~~or more~~ before the onset of reperfusion, and continuing for a period of more than 30 minutes after the onset of reperfusion.

10. (Previously presented) A method according to claim 9, wherein the cardioprotection is provided prior to, during, or following cardiac surgery.

11. (Previously presented) A method according to claim 9, wherein the cardioprotection is provided prior to, during, or following ischemic attack.
12. (Previously presented) A method according to claim 9, wherein the administering of the compound is continued for a period of more than 70 minutes after the onset of reperfusion.
13. (Previously presented) A method according to claim 9, wherein the compound is of the formula



or a pharmaceutically acceptable salt thereof.

14. (Previously presented) A method according to claim 9, wherein the compound is administered as a pharmaceutically acceptable salt thereof.
15. (Previously presented) A method according to claim 9, wherein the compound administered is contained in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of the compound.